Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 months

Documenti analoghi

• Agreement Between the Harmonized and the Self‐Explanatory Versions of the Revised ALS Functional Rating Scale in a Clinical Setting
  di: André Maier, et al.
  Pubblicazione: (2025)
• Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated ALS
  di: Sarah Bernsen, et al.
  Pubblicazione: (2025)
• In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis
  di: Joachim Schuster, et al.
  Pubblicazione: (2024)
• Combination of Serum Neurofilament Light Chain and Serum Cardiac Troponin T as Biomarkers Improves Diagnostic Accuracy in Amyotrophic Lateral Sclerosis
  di: Paula Lindenborn, et al.
  Pubblicazione: (2025)
• Atypical Facial Onset Weakness in SOD1 ALS
  di: Mark A. Garret, et al.
  Pubblicazione: (2025)